Term Asset-Backed Securities Loan Facility

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Monday, November 6, 2023

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 3,112,043,514 outstanding ordinary shares carrying voting rights (compared to 2,956,764,011 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Friday, November 3, 2023

Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,956,764,011 outstanding ordinary shares carrying voting rights (compared to 2,879,124,260 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Premier Health Secures Debt Financing for its Previously Announced Acquisition

Retrieved on: 
Monday, October 30, 2023

MONTREAL, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (“Premier Health” or the “Corporation”), a leading Canadian Healthtech company, is announcing a $50 million secured credit package (the “Secured Financing”) aimed at closing the acquisition of Solution Staffing Inc. (the “Transaction”), which was announced on July 4th, 2023, including a refinancing of its current revolving facility and new term loans to finance the Transaction.

Key Points: 
  • MONTREAL, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (“Premier Health” or the “Corporation”), a leading Canadian Healthtech company, is announcing a $50 million secured credit package (the “Secured Financing”) aimed at closing the acquisition of Solution Staffing Inc. (the “Transaction”), which was announced on July 4th, 2023, including a refinancing of its current revolving facility and new term loans to finance the Transaction.
  • The other three loans have fixed rates averaging 14.3%.
  • The Secured Financing is led by the Royal Bank of Canada and BDC Capital Inc., sole affiliate of the Business Development Bank of Canada and is subject to certain conditions precedents, mainly the conclusion of the Transaction and other customary conditions.
  • Collateral security for the Secured Financing will be provided by PHA and its subsidiaries.

Beedie Investments Ltd. Enters into an Amendment of Convertible Loan Facility with Metalla Royalty & Streaming Ltd.

Retrieved on: 
Monday, October 23, 2023

Vancouver, British Columbia--(Newsfile Corp. - October 23, 2023) - Beedie Investments Ltd. ("Beedie") has entered into a second amended and restated convertible loan agreement dated October 19, 2023 (the "Amended & Restated Loan Agreement") with Metalla Royalty & Streaming Ltd. ("Metalla"), pursuant to which the parties agreed to amend the terms of the existing convertible loan agreement (the "Company Convertible Loan") between Beedie and Metalla (the "Loan Facility"), which will become effective as of the closing of the previously-announced business combination transaction (the "Transaction") involving Metalla and Nova Royalty Corp. ("Nova").

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - October 23, 2023) - Beedie Investments Ltd. ("Beedie") has entered into a second amended and restated convertible loan agreement dated October 19, 2023 (the "Amended & Restated Loan Agreement") with Metalla Royalty & Streaming Ltd. ("Metalla"), pursuant to which the parties agreed to amend the terms of the existing convertible loan agreement (the "Company Convertible Loan") between Beedie and Metalla (the "Loan Facility"), which will become effective as of the closing of the previously-announced business combination transaction (the "Transaction") involving Metalla and Nova Royalty Corp. ("Nova").
  • Conversion of the Subscription Receipts into Common Shares is conditional upon completion of the Transaction and certain other conditions.
  • Conversion of the Subscription Receipts into Common Shares is conditional upon completion of the Transaction and certain other conditions.
  • All of the securities held by Beedie in Metalla, including the Common Shares and the Amended & Restated Convertible Loan Agreement, are being held for investment purposes.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Friday, October 20, 2023

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,879,124,260 outstanding ordinary shares carrying voting rights (compared to 2,758,351,314 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Tuesday, October 10, 2023

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,758,351,314 outstanding ordinary shares carrying voting rights (compared to 2,667,771,604 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates

Retrieved on: 
Tuesday, September 26, 2023

The MD&A and the unaudited consolidated financial statements can be found at www.sedarplus.ca , on EDGAR at www.sec.gov and at www.theratech.com .

Key Points: 
  • The MD&A and the unaudited consolidated financial statements can be found at www.sedarplus.ca , on EDGAR at www.sec.gov and at www.theratech.com .
  • Trogarzo® net sales in the third quarter of fiscal 2023 amounted to $7,672,000 compared to $7,935,000 for the same quarter of 2022, representing a decrease of 3.3% year-over-year.
  • As the other asset was fully amortized during fiscal 2022, amortization of the other asset in fiscal 2023 is nil.
  • There were no other significant financing activities or investing activities in the three and nine months ended August 31, 2023, and 2022.

Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility

Retrieved on: 
Monday, September 25, 2023

MONTREAL, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has reached an agreement in principle to amend some of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time (the “Loan Facility”), with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, “Marathon”).

Key Points: 
  • MONTREAL, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has reached an agreement in principle to amend some of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time (the “Loan Facility”), with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager (collectively, “Marathon”).
  • Following the share consolidation completed on July 31, 2023, the exercise of four Warrants is required to purchase 1 common share of Theratechnologies, resulting in a maximum issuance of 1,250,000 common shares.
  • The Warrants can be exercised until February 27, 2030.
  • The amendments to the Loan Facility are expected to be executed on or about October 10, 2023.

Credit Acceptance Announces Extension of Revolving Secured Warehouse Facility

Retrieved on: 
Thursday, September 21, 2023

Southfield, Michigan, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) announced today that we extended the date on which our $200.0 million revolving secured warehouse facility will cease to revolve from September 1, 2024 to September 21, 2026.

Key Points: 
  • Southfield, Michigan, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) announced today that we extended the date on which our $200.0 million revolving secured warehouse facility will cease to revolve from September 1, 2024 to September 21, 2026.
  • The interest rate on borrowings under the facility has increased from Secured Overnight Financing Rate (“SOFR”) plus 201.4 basis points to SOFR plus 225 basis points.
  • Since 1972, Credit Acceptance has offered financing programs that enable automobile dealers to sell vehicles to consumers, regardless of their credit history.
  • Credit Acceptance is publicly traded on the Nasdaq Stock Market under the symbol CACC.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Monday, September 18, 2023

Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,667,771,604 outstanding ordinary shares carrying voting rights (compared to 2,551,311,977 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.